OSR Health

OSRH

시가총액 US$409만

The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline   BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders. To OSR Health Shareholders: I am aware that many of you are watching closely to see what comes next.

BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination") from the Nasdaq Listing Qualifications Department notifying the Company that its common stock and warrants are subject to delisting from The Nasdaq Capital Market as a result of the Company's failure to regain compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Nasdaq Hearing Request The Company intends to request a hearing before the Nasdaq Independent Hearings Panel (the "Panel") to appeal the Staff Determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.

Company cites extraordinary trading activity, global shareholder support, and continued commitment to Nasdaq compliance and the CVR program. BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders.

Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders. Dear Shareholders, Today marks five business days before August 18, the practical deadline by which the Nasdaq is expected to communicate its determination regarding OSRH's continued listing if our stock price has not regained the minimum bid price requirement of $1.00 per share as of the market close.

BELLEVUE, WA / ACCESS Newswire / August 7, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning the Nasdaq Stock Market ("Nasdaq") and the Company's Shareholder Loyalty CVR Program. The Company is clarifying that the statement in the prior release, "The communication affirms that our loyalty program is additive and gives shareholders clarity," should not be interpreted as indicating that Nasdaq has approved or endorsed the Shareholder Loyalty CVR Program.

Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months BELLEVUE, WA / ACCESS Newswire / August 3, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma. Prof. Wolfgang Wick, M.D.

BELLEVUE, WA / ACCESS Newswire / July 31, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that the Nasdaq Stock Market ("Nasdaq") stated in a verbal communication with the Company that the Company's Shareholder Loyalty Contingent Value Rights (CVR) program will not result in any mechanical adjustment to the price of OSR Health's common stock - either upon the distribution of the CVRs or upon the delivery of additional shares of common stock to enrolled holders under the program. What this means for shareholders: No mechanical price adjustment.

BELLEVUE, WA / ACCESS Newswire / July 13, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from Chief Executive Officer to shareholders. To Every OSR Health Shareholder: OSR Health is at an inflection point - one that I believe will be looked back upon as the moment this company's underlying value began to be recognized by the broader market.

NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00. The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split.

Contingent Value Rights would reward continuous holders with additional shares as the Company meets defined price milestones BELLEVUE, WA / ACCESS Newswire / June 25, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today announced a Shareholder Loyalty Program designed to reward the investors who hold OSRH stock over the long term. Under the program, the Company plans to distribute non-transferable Contingent Value Rights ("CVRs") to all shareholders of record tentatively as of July 31, 2026.